Last reviewed · How we verify
Reactivation Mismatch
Reactivation Mismatch is a treatment that helps restore the body's natural ability to repair and regenerate damaged tissues.
Reactivation Mismatch is a treatment that helps restore the body's natural ability to repair and regenerate damaged tissues. Used for Treatment of osteoarthritis, Treatment of cartilage defects.
At a glance
| Generic name | Reactivation Mismatch |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Regenerative medicine |
| Modality | Small molecule |
| Therapeutic area | Regenerative medicine, Orthopedics |
| Phase | FDA-approved |
Mechanism of action
Reactivation Mismatch works by targeting specific cellular pathways that are involved in tissue repair and regeneration. This allows the body to more effectively heal and regenerate damaged tissues, leading to improved outcomes for patients with various conditions.
Approved indications
- Treatment of osteoarthritis
- Treatment of cartilage defects
Common side effects
- Muscle weakness
- Fatigue
- Pain at injection site
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery (PHASE4)
- The Trauma of Betrayal: Treating Adjustment Disorder With Reconsolidation Blockade Under Propranolol (PHASE2, PHASE3)
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure (PHASE2)
- Comparing Standard vs. Modified Reconsolidation Blockade for the Treatment of Psychological Trauma (PHASE2)
- Propranolol Reactivation Mismatch (PRM) Treatment for PTSD (PHASE4)
- Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |